Total Funding
23
41
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
131092
Concert Pharmaceuticals is a biotechnology company that uses deuterium chemistry to develop drug products that address patient needs.
Acquired by 
Sun Pharmaceutical
Roger Tung: Founder, President, CEO & Board of DirectorsPast Role: Vertex Pharmaceuticals, Founding Scientist
Richard Aldrich: Co - FounderPast Role: Vertex Pharmaceuticals, SVP / Chief Business Officer
About the Company
Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.
Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of
new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.
